These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 11249826

  • 1. Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
    Amábile-Cuevas CF, Hermida-Escobedo C, Vivar R.
    Clin Infect Dis; 2001 Mar 15; 32 Suppl 1():S30-2. PubMed ID: 11249826
    [Abstract] [Full Text] [Related]

  • 2. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
    Esposito S, Noviello S, Ianniello F.
    J Chemother; 2000 Dec 15; 12(6):475-81. PubMed ID: 11154028
    [Abstract] [Full Text] [Related]

  • 3. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H.
    J Antimicrob Chemother; 2009 May 15; 63(5):886-94. PubMed ID: 19279051
    [Abstract] [Full Text] [Related]

  • 4. Oral antimicrobial susceptibilities of Streptococcus pyogenes recently isolated in five countries.
    Bandak SI, Turnak MR, Allen BS, Bolzon LD, Preston DA.
    Int J Clin Pract; 2000 Nov 15; 54(9):585-8. PubMed ID: 11220986
    [Abstract] [Full Text] [Related]

  • 5. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S, Ianniello F, Leone S, Esposito S.
    J Antimicrob Chemother; 2003 Nov 15; 52(5):869-72. PubMed ID: 14519672
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH, Wang JT, Chen YC, Chang SC, Luh KT.
    J Microbiol Immunol Infect; 2001 Sep 15; 34(3):178-84. PubMed ID: 11605808
    [Abstract] [Full Text] [Related]

  • 7. [Comparative in vitro activity of new oral macrolides against Streptococcus pyogenes strains].
    Prado V, Romero J, Herrera N, Marinkovic K, Bustos R.
    Rev Med Chil; 1993 Oct 15; 121(10):1128-34. PubMed ID: 8191116
    [Abstract] [Full Text] [Related]

  • 8. [Isolated susceptibility of Streptococcus pyogenes to 3 macrolides].
    Sakran W, Raz R, Colodner R, Keness Y.
    Harefuah; 1997 Nov 02; 133(9):365-6, 414. PubMed ID: 9418339
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of moxifloxacin compared to other antimicrobials against streptococci isolated from iatrogenic oral bacteremia in Spain.
    Tomás I, Alvarez M, Limeres J, Otero JL, Saavedra E, López-Meléndez C, Diz P.
    Oral Microbiol Immunol; 2004 Oct 02; 19(5):331-5. PubMed ID: 15327647
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial susceptibility and macrolide resistance genes in Streptococcus pyogenes collected in Austria and Hungary.
    Gattringer R, Sauermann R, Lagler H, Stich K, Buxbaum A, Graninger W, Georgopoulos A.
    Int J Antimicrob Agents; 2004 Sep 02; 24(3):290-3. PubMed ID: 15325435
    [Abstract] [Full Text] [Related]

  • 11. [Emergence of resistance to macrolides in Streptococcus pyogenes].
    Vinagre C, Cifuentes M, Valdivieso F, Ojeda A, Prado V.
    Rev Med Chil; 1999 Dec 02; 127(12):1447-52. PubMed ID: 10835751
    [Abstract] [Full Text] [Related]

  • 12. [Macrolide antibiotic resistance rates and phenotypes of group A beta hemolytic streptococci isolated between the years 1999-2000 and 2001-2002].
    Senses Z, Baysallar M, Gür D, Doğanci L.
    Mikrobiyol Bul; 2003 Oct 02; 37(4):225-34. PubMed ID: 14748258
    [Abstract] [Full Text] [Related]

  • 13. Susceptibility of Streptococcus pyogenes to two macrolides in northern Israel.
    Sakran W, Raz R, Chazan B, Koren A, Colodner R.
    Int J Antimicrob Agents; 2004 May 02; 23(5):517-9. PubMed ID: 15120735
    [Abstract] [Full Text] [Related]

  • 14. Activity of ceftibuten, cefaclor, azithromycin, clarithromycin, erythromycin and telithromycin against Streptococcus pyogenes clinical isolates with different genotypes and phenotypes.
    Drago L, Ripa S, Zampaloni C, De Vecchi E, Vitali LA, Petrelli D, Prenna M.
    Chemotherapy; 2005 Aug 02; 51(5):268-71. PubMed ID: 16088124
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of moxifloxacin compared to other fluoroquinolones against different erythromycin-resistant phenotypes of group A beta-hemolytic streptococcus.
    Esposito S, Noviello S, Ianniello F, Novelli A.
    Chemotherapy; 2000 Aug 02; 46(1):23-7. PubMed ID: 10601794
    [Abstract] [Full Text] [Related]

  • 16. Intrinsic reduced susceptibility of serotype 6 Streptococcus pyogenes to fluoroquinolone antibiotics.
    Orscheln RC, Johnson DR, Olson SM, Presti RM, Martin JM, Kaplan EL, Storch GA.
    J Infect Dis; 2005 Apr 15; 191(8):1272-9. PubMed ID: 15776373
    [Abstract] [Full Text] [Related]

  • 17. Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae.
    Esposito S, Noviello S, Ianniello F.
    Chemotherapy; 2001 Apr 15; 47(2):90-6. PubMed ID: 11173809
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
    Brown SD, Rybak MJ.
    J Antimicrob Chemother; 2004 Aug 15; 54 Suppl 1():i7-15. PubMed ID: 15265831
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
    Schentag JJ.
    J Chemother; 2002 Feb 15; 14 Suppl 2():13-21. PubMed ID: 12003136
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.